2.09
前日終値:
$1.96
開ける:
$2
24時間の取引高:
4.12M
Relative Volume:
1.43
時価総額:
$243.61M
収益:
$6.65M
当期純損益:
$-136.32M
株価収益率:
-1.821
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
+6.09%
1か月 パフォーマンス:
+20.81%
6か月 パフォーマンス:
+99.05%
1年 パフォーマンス:
+72.73%
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics Inc
|
2.09 | 243.61M | 6.65M | -136.32M | -112.04M | -1.1477 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-19 | 再開されました | Jefferies | Buy |
| 2025-10-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | ダウングレード | Stifel | Buy → Hold |
| 2023-01-06 | ダウングレード | Truist | Buy → Hold |
| 2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-07-28 | 開始されました | Needham | Hold |
| 2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
| 2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Jefferies | Buy |
| 2021-02-26 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
| 2020-05-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 繰り返されました | Mizuho | Buy |
| 2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-06-07 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 開始されました | Jefferies | Buy |
| 2018-08-01 | 開始されました | Citigroup | Buy |
| 2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey
Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fate Therapeutics Inc (FATE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fate Therapeutics Inc (FATE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan
Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan
Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant - Stock Titan
Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant - Stock Titan
Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options - Stock Titan
Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) - Stock Titan
[8-K] FATE THERAPEUTICS INC Reports Material Event - Stock Titan
Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo - AD HOC NEWS
Fate Therapeutics Appoints Laura Hamill To Board Of Directors - TradingView
Fate Therapeutics appoints Laura Hamill to board of directors - Investing.com
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo Finance
Fate Therapeutics Appoints Laura Hamill to Board of Directors - GlobeNewswire
Fate Therapeutics (FATE) Q1 2026 Earnings: EPS Beat on Cost Discipline, Pipeline Progress Drives Stock HigherSegment Revenue Breakdown - newsline.com
FATE Stock Price, Quote & Chart - ChartMill
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Insider Monkey
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FATE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $7.00 - GuruFocus
H.C. Wainwright reiterates Fate Therapeutics stock rating on SLE data By Investing.com - Investing.com Canada
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Fate Therapeutics Advances Off-the-Shelf CAR T-Cell Therapies for Autoimmune Diseases and Cancer – Clinical Pipeline and 2026 Updates - Minichart
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline - TipRanks
Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash - TradingView
Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028 - Stock Titan
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - markets.businessinsider.com
Fate Therapeutics presents autoimmune therapy data at EULAR - Investing.com
Fate Therapeutics presents autoimmune therapy data at EULAR By Investing.com - Investing.com South Africa
Fate Therapeutics Showcases Data from FT819 and FT839 - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Off-the-shelf FT836 shrinks tumors in colorectal cancer without conditioning chemo - Stock Titan
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting - GlobeNewswire
Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? - Yahoo Finance
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
Fate Therapeutics Rallies 9.5% as FATE Stock Breaks Above Key Support LevelShort Setup Alerts - newsline.com
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):